# Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Source: https://onco.cc/trials/nct05544552/  
OnCo record `nct05544552` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TYRA-300 in bladder & urothelial cancer, run by Tyra Biosciences, Inc, active and no longer recruiting.

## Summary

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations is a phase 1/2 interventional study registered as NCT05544552 by Tyra Biosciences, Inc, with 310 participants enrolled, started 2022-11-22 and due to reach its primary completion in 2026-11. Interventions recorded: TYRA-300.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05544552
- Phase: 1/2
- Setting: A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)
- Sponsor: Tyra Biosciences, Inc
- Enrolled: 310

## Sources

- ClinicalTrials.gov NCT05544552: https://clinicaltrials.gov/study/NCT05544552

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [TYRA-300](https://onco.cc/drugs/tyra-300/)
- companies: [Tyra Biosciences](https://onco.cc/companies/tyra-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05544552.json